MedTrace Logo

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

NCT02665910 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-04-19

No results posted yet for this study

Summary

Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized

Conditions

Interventions

DRUG

SHR0302

Oral tablets (1 mg, 5 mg, 10 mg)

DRUG

SHR0302 placebo comparator

Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pei Hu, PhD · Peking Union Medical College Hospital

  • Xiaofeng Zeng, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02665910 on ClinicalTrials.gov